Background
Imaprelimab (PRX-003) is a humanized IgG1κ anti-melanoma cell adhesion molecule (MCAM) monoclonal antibody. Imaprelimab is an antineoplastic agent.• The progression associated antigen MUC18: a unique member of the immunoglobulin supergene family., PMID:8292890• Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8., PMID:16965268• Melanoma-associated adhesion molecule MUC18/MCAM (CD146) and transcriptional regulator mader in normal human CNS., PMID:9730695• The role of CD146 (Mel-CAM) in biology and pathology., PMID:10451481• MCAM/MUC18/CD146 as a Multifaceted Warning Marker of Melanoma Progression in Liquid Biopsy., PMID:34830300• Galectin-3 interacts with the cell-surface glycoprotein CD146 (MCAM, MUC18) and induces secretion of metastasis-promoting cytokines from vascular endothelial cells., PMID:28364041• Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis., PMID:19703903• Melanoma progression-associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand., PMID:9398060• A novel function of MUC18: amplification of lung inflammation during bacterial infection., PMID:23256918• Keratinocytes express the CD146 (Muc18/S-endo) antigen in tissue culture and during inflammatory skin diseases., PMID:10951239